Brisbane, Calif.-based Humanigen Inc. named Tarek Sahmoud as its chief medical officer.
Sahmoud consults a number of chimeric antigen receptor T cell therapy companies on their clinical and regulatory plans.
He recently served as the chief medical officer for Eisai Co. Ltd.'s unit H3 Biomedicine Inc., a biopharmaceutical company engaged in the discovery and development of small-molecule drugs to treat cancer.
Humanigen is developing CAR-T optimization and cancer treatments.
